Showing results (151-160 of 1,988) with videos related to

Sort By:
Pageof 199
Prostate Cancer and Prostatic Diseases|December 14, 2016
Updated postoperative nomogram incorporating the number of positive lymph nodes to predict disease recurrence following radical prostatectomyD P Nguyen, M Kent, A Vilaseca, et al.
Prostate Cancer and Prostatic Diseases|November 2, 2016
Active surveillance for intermediate-risk prostate cancerM A Dall'Era, L Klotz
Prostate Cancer and Prostatic Diseases|March 22, 2017
ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter studyI Heidegger, H Klocker, R Pichler, et al.
Prostate Cancer and Prostatic Diseases|April 12, 2017
Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based studyH-J Shih, M-C Kao, P-S Tsai, et al.
Prostate Cancer and Prostatic Diseases|April 12, 2017
Trends in the use of radiation therapy for stage IIA prostate cancer from 2004 to 2013: a retrospective analysis using the National Cancer DatabaseT Malouff, N W Mathy, S Marsh, et al.
Prostate Cancer and Prostatic Diseases|March 26, 2014
Novel bone-targeting agents in prostate cancerC Albany, N M Hahn
Prostate Cancer and Prostatic Diseases|January 11, 2017
Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort studyC B Chen, D T Eurich, S R Majumdar, et al.
Prostate Cancer and Prostatic Diseases|January 25, 2017
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAILA H Bryce, J J Alumkal, A Armstrong, et al.
Prostate Cancer and Prostatic Diseases|January 4, 2017
Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive diseaseJ J Tosoian, R Alam, C Gergis, et al.
Prostate Cancer and Prostatic Diseases|January 4, 2017
Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trialsF Saad, C Ivanescu, D Phung, et al.
Pageof 199